Novo Nordisk strikes second licensing deal since frosty capital-markets day
MarketWatchPaywall
Read Full Article at MarketWatch →Ad Slot — In-Article (728x90)
Novo Nordisk said Tuesday the company struck its second licensing deal since it received a poor reception from investors after presenting its long-term strategy.
This is a summary. For the full story, read the original article at MarketWatch.
Original source: MarketWatch